2018
What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial?
INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.Peer-Reviewed Original ResearchTransient ischemic attackDensity lipoprotein cholesterolInsulin resistanceCV benefitsLog HRCardiovascular benefitsLipoprotein cholesterolBlood pressureStroke/transient ischemic attackHigh-sensitivity C-reactive proteinHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMeasures of IRInsulin Resistance InterventionHomeostatic model assessmentDiastolic blood pressureEffect of pioglitazoneSystolic blood pressureC-reactive proteinFavorable effectBoehringer Ingelheim PharmaceuticalsPIO effectIschemic attackNondiabetic patientsHOMA-IR
2005
Racial Disparities in Stroke Risk Factors
Bravata DM, Wells CK, Gulanski B, Kernan WN, Brass LM, Long J, Concato J. Racial Disparities in Stroke Risk Factors. Stroke 2005, 36: 1507-1511. PMID: 15961710, DOI: 10.1161/01.str.0000170991.63594.b6.Peer-Reviewed Original ResearchConceptsStroke risk factorsRisk factorsStroke historyHigh prevalenceLow high-density lipoprotein cholesterolHigher C-reactive proteinHigh-density lipoprotein cholesterolCommunity-dwelling stroke survivorsC-reactive proteinThird National HealthSevere strokeLipoprotein cholesterolMyocardial infarctionNational HealthStroke survivorsNutrition SurveyHigh incidenceUS populationStrokeOlder ageCross-sectional samplePrevalenceRacial disparitiesEthnic differencesAssociation